Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fentanyl, quantity: 2.55 mg - drug delivery system, transdermal - excipient ingredients: dimeticone 360; polyethylene terephthalate; polyvinylidene flouride; methylated trimethylated silica; heptane; titanium dioxide; potable water; trolamine; strong ammonia solution; industrial methylated spirit; styrene/acrylates copolymer; polyethylene; polytef; dimeticone 350; docusate sodium; propylene glycol; purified water; acrylates copolymer; methoxyisopropyl acetate; 2-ethylhexyl acrylate; ethyl acetate; polyisocyanate; 4,4'-diphenylmethane diisocyanate; silane; polypropylene; ethylene/propylene copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate; tris(2,4-ditert-butyphenyl) phosphite; calcium stearate; aluminium magnesium hydroxide carbonate; perflouropropylene/vinylidene diflouride copolymer; 1,3,5-trimethyl-2,4,6-tris(3,5-ditert-butyl-4-hydroxybenzyl)benzene; aluminium calcium sodium silicate; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; iron oxide red; pigment yellow 119; zinc stearate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fentanyl, quantity: 10.2 mg - drug delivery system, transdermal - excipient ingredients: dimeticone 360; methylated trimethylated silica; heptane; ethyl acetate; polyisocyanate; 4,4'-diphenylmethane diisocyanate; silane; polyethylene terephthalate; polyethylene; titanium dioxide; polypropylene; ethylene/propylene copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate; tris(2,4-ditert-butyphenyl) phosphite; calcium stearate; aluminium magnesium hydroxide carbonate; perflouropropylene/vinylidene diflouride copolymer; 1,3,5-trimethyl-2,4,6-tris(3,5-ditert-butyl-4-hydroxybenzyl)benzene; aluminium calcium sodium silicate; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; iron oxide red; pigment yellow 119; zinc stearate; potable water; trolamine; strong ammonia solution; industrial methylated spirit; styrene/acrylates copolymer; polytef; dimeticone 350; docusate sodium; propylene glycol; purified water; acrylates copolymer; methoxyisopropyl acetate; 2-ethylhexyl acrylate; polyvinylidene flouride - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fentanyl, quantity: 1.28 mg - drug delivery system, transdermal - excipient ingredients: dimeticone 360; titanium dioxide; potable water; trolamine; strong ammonia solution; industrial methylated spirit; styrene/acrylates copolymer; polyethylene; polytef; dimeticone 350; docusate sodium; propylene glycol; purified water; acrylates copolymer; methoxyisopropyl acetate; 2-ethylhexyl acrylate; polyethylene terephthalate; polyvinylidene flouride; methylated trimethylated silica; heptane; ethyl acetate; polyisocyanate; 4,4'-diphenylmethane diisocyanate; silane; polypropylene; ethylene/propylene copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate; tris(2,4-ditert-butyphenyl) phosphite; calcium stearate; aluminium magnesium hydroxide carbonate; perflouropropylene/vinylidene diflouride copolymer; 1,3,5-trimethyl-2,4,6-tris(3,5-ditert-butyl-4-hydroxybenzyl)benzene; aluminium calcium sodium silicate; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; iron oxide red; pigment yellow 119; zinc stearate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fentanyl, quantity: 7.65 mg - drug delivery system, transdermal - excipient ingredients: dimeticone 360; methylated trimethylated silica; heptane; polyethylene terephthalate; polyvinylidene flouride; ethyl acetate; polyisocyanate; 4,4'-diphenylmethane diisocyanate; silane; polyethylene; titanium dioxide; polypropylene; ethylene/propylene copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate; tris(2,4-ditert-butyphenyl) phosphite; calcium stearate; aluminium magnesium hydroxide carbonate; perflouropropylene/vinylidene diflouride copolymer; 1,3,5-trimethyl-2,4,6-tris(3,5-ditert-butyl-4-hydroxybenzyl)benzene; aluminium calcium sodium silicate; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; iron oxide red; pigment yellow 119; zinc stearate; potable water; trolamine; strong ammonia solution; industrial methylated spirit; styrene/acrylates copolymer; polytef; dimeticone 350; docusate sodium; propylene glycol; purified water; acrylates copolymer; methoxyisopropyl acetate; 2-ethylhexyl acrylate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fentanyl, quantity: 5.1 mg - drug delivery system, transdermal - excipient ingredients: dimeticone 360; methylated trimethylated silica; heptane; polyethylene terephthalate; polyvinylidene flouride; titanium dioxide; potable water; trolamine; strong ammonia solution; industrial methylated spirit; styrene/acrylates copolymer; polyethylene; polytef; dimeticone 350; docusate sodium; propylene glycol; purified water; acrylates copolymer; methoxyisopropyl acetate; 2-ethylhexyl acrylate; ethyl acetate; polyisocyanate; 4,4'-diphenylmethane diisocyanate; silane; polypropylene; ethylene/propylene copolymer; pentaerythrityl tetra-di-t-butyl hydroxyhydrocinnamate; tris(2,4-ditert-butyphenyl) phosphite; calcium stearate; aluminium magnesium hydroxide carbonate; perflouropropylene/vinylidene diflouride copolymer; 1,3,5-trimethyl-2,4,6-tris(3,5-ditert-butyl-4-hydroxybenzyl)benzene; aluminium calcium sodium silicate; octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate; iron oxide red; pigment yellow 119; zinc stearate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.

Spojené státy - angličtina - NLM (National Library of Medicine)

parfums christian dior - zinc oxide  18.70%, octinoxate  7.49%, titanium dioxide  2.13%, oxybenzone  2.00%, sunscreen - - helps prevent sunburn. - if used as directed with other sun protection measures (see direction), decreases the risk of skin cancer and early skin aging caused by the sun.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - panitumumab, quantity: 400 mg - injection, concentrated - excipient ingredients: sodium acetate trihydrate; sodium chloride; water for injections - vectibix is indicated for the treatment of patients with wild-type ras metastatic colorectal cancer (mcrc) (see precautions laboratory tests): - as first line therapy in combination with folfox. efficacy may be influenced by patient performance status (see clinical trials; precautions). - as second line therapy in combination with folfiri for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). efficacy may be influenced by patient performance status (see clinical trials). - as monotherapy in patients after the failure of standard chemotherapy.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - panitumumab, quantity: 100 mg - injection, concentrated - excipient ingredients: sodium chloride; sodium acetate trihydrate; water for injections - vectibix is indicated for the treatment of patients with wild-type ras metastatic colorectal cancer (mcrc) (see precautions laboratory tests): - as first line therapy in combination with folfox. efficacy may be influenced by patient performance status (see clinical trials; precautions). - as second line therapy in combination with folfiri for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan). efficacy may be influenced by patient performance status (see clinical trials). - as monotherapy in patients after the failure of standard chemotherapy.

Spojené státy - angličtina - NLM (National Library of Medicine)

sweat cosmetics, inc. - zinc oxide 20% - sunscreen helps prevent sunburn

Spojené státy - angličtina - NLM (National Library of Medicine)

supergoop, llc - zinc oxide (unii: soi2loh54z) (zinc oxide - unii:soi2loh54z) - - sunscreen - helps prevent sunburn - if used as directed with other sun protection measures (see directions ), decreases the risk of skin cancer and early skin aging caused by the sun stop use and ask a doctor if rash occurs.